Andreas Lingnau

Andreas Lingnau has extensive experience in the field of in vivo pharmacology and pathology. Andreas is currently the Director of in vivo Pharmacology & Pathology at MorphoSys since November 2019. Prior to joining MorphoSys, Andreas worked as an Associate Director in the "New Antibody Products" Cluster at Genmab B.V. from August 2018 to November 2019. In this role, they were responsible for the growth of the "Preclinical in vivo Pharmacology" team and the evaluation of new antibodies and antibody formats for cancer treatment. Before that, Andreas held the position of Principal Scientist in the "Translational Research in Pharmacology (TR&P)" group at Genmab B.V. from August 2014 to August 2018. During this time, they planned and conducted in vivo projects to test the efficacy of novel antibodies and antibody formats in oncology. Prior to Genmab B.V., Andreas worked at ProQinase GmbH from July 2009 to August 2014, where they held various roles including Head of "In Vivo Pharmacology," Head of the Animal Facility, and Group Leader in "In Vivo Cancer Mouse Models." Andreas also worked at Oncotest GmbH as a Project Leader in "In Vivo/Histology, Oncology" from April 2009 to June 2009. Earlier in their career, Andreas worked at ProQinase GmbH and Tumor Biology Center as a Group Leader in "Cancer Drug Identification and Validation" from January 2001 to March 2009, and at VM-PRO GmbH as a Research Associate in Parasitological Diagnostics from April 1999 to December 2000. Throughout their career, Andreas focused on the development and evaluation of antibody-based diagnostic tests and the study of novel cancer drugs and therapies.

Andreas Lingnau's education history begins with their enrollment at the University of Bochum from 1986 to 1989. It is not specified what degree they pursued during this time. After completing their studies at Bochum, Lingnau went on to attend the University of Bonn from 1989 to 1993, where they obtained a Diploma in Biology. Following this, they joined GBF, National Research Center for Biotechnology, Dept. of Cell Biology and Immunology from 1993 to 1996. At GBF, they completed their Ph.D., although the specific field of study is not provided. Finally, from 1996 to 1999, Lingnau attended Washington University – School of Medicine in St. Louis, USA, where they pursued a postdoctoral degree.